The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 25.60
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.20 (4.80%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 25.60
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

Thu, 25th Mar 2021 11:28

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Tandem Group, up 14% at 653.60 pence, 12-month range 113.26p-669p. The sports equipment distributor says 2020 pretax profit was GBP4.0 million, up 60% from GBP2.5 million in 2019 on revenue of GBP37.1 million, down 4.6% from GBP38.8 million in 2019. Declares final dividend of 5.50p per share, up from 5.04p in 2019. Looking ahead, says it has made an encouraging start to 2021 and is optimistic about the outlook.

----------

Oncimmune Holdings, up 8.3% at 185.78p, 12-month range 43.25p-222p. The immunodiagnostics company will raise GBP9.0 million from a placing of 5.0 million shares at 180p. Oncimmune conducting the fund raise to invest in ImmunoINSIGHTS business. Placing price represents a premium of 5.0% to closing price of 171.5p on Wednesday.

----------

AIM - LOSERS

----------

Genedrive, down 27% at 84.75p, 12-month range 11.07p-302.60p. The molecular diagnostics firm swings to a first half pretax profit of GBP621,000 from a GBP3.3 million loss a year before on revenue of GBP355,000, down from GBP627,000. Says it continues to experience delays in gaining the key regulatory approvals from the US FDA, WHO and in India. Company is focusing on larger commercial opportunities in the Covid-19 space and expects progression from strategy in the coming months.

----------

Starcom, down 16% at 0.80p, 12-month range 0.72p-1.34p. The remote tracking systems firm posts 2020 operating loss of USD1.8 million, widened from USD706,000 loss in 2019 on revenue down to USD5.0 million from USD6.8 million in 2019.

----------

SpaceandPeople, down 14% at 8.65p, 12-month range 3.7p-19.6p. The promotional and brand experience specialist says trading during the second half of 2020 remained extremely challenging as further lockdowns in the UK and Germany affected the ability to operate. SpaceandPeople expects to swing to 2020 pretax loss of around GBP2.5 million from profit of GBP10,000 in 2019.

----------

Ebiquity, down 9.6% at 26.5p, 12-month range 17.1p-33p. The marketing and media consultancy says annual results reflect effects of Covid-19 pandemic on global advertising and client budgets. Ebiquity says 2020 pretax loss narrows to GBP3.9 million from GBP5.7 million in 2019 on revenue GBP55.9 million, down from GBP68.1 million. Ebiquity not proposing dividend for 2020 due to Covid-19 uncertainty.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Mar 2020 12:57

Oncimmune EarlyCDT Lung Test Launched In US By Commercial Partner

Oncimmune EarlyCDT Lung Test Launched In US By Commercial Partner

Read more
12 Feb 2020 09:10

Oncimmune Half-Year Loss Widens As Business "Reshaping" Ups Expenses

Oncimmune Half-Year Loss Widens As Business "Reshaping" Ups Expenses

Read more
28 Jan 2020 13:52

Oncimmune Reports Study Results For Cancer Test Product

Oncimmune Reports Study Results For Cancer Test Product

Read more
22 Nov 2019 16:05

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Nov 2019 13:33

Oncimmune And Biodesix Complete US Agreement For Lung Cancer Test

Oncimmune And Biodesix Complete US Agreement For Lung Cancer Test

Read more
31 Oct 2019 11:38

Oncimmune Annual Loss Deepens On Costs But Makes Operational Progress

Oncimmune Annual Loss Deepens On Costs But Makes Operational Progress

Read more
25 Sep 2019 11:32

CORRECT (Sep 20): Oncimmune Secures EUR8.5 Million Credit Facility

CORRECT (Sep 20): Oncimmune Secures EUR8.5 Million Credit Facility

Read more
23 Sep 2019 16:08

Oncimmune Adds Former Glaxo And Astra Seniors To Leadership Ranks

Oncimmune Adds Former Glaxo And Astra Seniors To Leadership Ranks

Read more
20 Sep 2019 15:47

Oncimmune funded into 2021 with new EUR 8.5m facility

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings has secured a credit facility of €8.5m (£7.5m) with IPF Management, it announced on Friday.

Read more
20 Sep 2019 14:04

Oncimmune Secures EUR8.5 Billion Debt For Products Commercialisation

(Alliance News) - Oncimmune Holdings PLC on Friday said it has secured a credit facility of EUR8.5 million with IPF Management SA.The immunodiagnostics company said it will immediately draw

Read more
9 Sep 2019 12:07

Oncimmune "Thrilled" With EarlyCDT Lung Cancer Test Trial Result

(Alliance News) - Oncimmune Holdings PLC on Monday announced positive results from a trial of its EarlyCDT Lung test to detect early stage lung cancer.Shares in Oncimmune were up 5.5% at in

Read more
15 Jul 2019 12:55

Oncimmune Further Expands EarlyCDT Lung Sales In Spain Through Vithas

(Alliance News) - Oncimmune Holdings PLC on Monday said Sabartech SL, its existing distributor in Spain and Portugal, has agreed with Vithas Group to sell EarlyCDT Lung as a screening test for of

Read more
28 Jun 2019 11:03

Oncimmune sells US operations to and partners with Biodesix

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings has entered into an exclusive partnership agreement, it announced on Friday, which it said could "unlock the full potential" of its 'EarlyCDT Lung' product in the United States.

Read more
26 Jun 2019 10:58

Oncimmune confident of 'material profitable revenues'

(Sharecast News) - Immunodiagnostics firm Oncimmune told investors on Wednesday it was confident it could generate "material profitable revenues" on the back of several business developments.

Read more
4 Jun 2019 09:56

Oncimmune Holdings Reports Positive Lung Cancer Study Results

LONDON (Alliance News) - Oncimmune Holdings PLC on Tuesday reported positive top line results from its early cancer detection test in patients with lung cancer.Oncimmune Holdings shares at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.